Cancer Immunotherapy Market By Cancer Type | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cancer Immunotherapy Market
Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodie, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021)
Report Code : HCR 0197
Updated Date: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Cancer Immunotherapy – Market Overview
2. Executive Summary 
3. Cancer Immunotherapy Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Cancer Immunotherapy – Market Forces
   4.1. Drivers
      4.1.1. Increasing awareness and instances of cancer
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cancer Immunotherapy Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Cancer Immunotherapy Market, By Cancer Type
   6.1. Cancer monoclonal antibodies
      6.1.1. Naked monoclonal antibodies 
      6.1.2. Conjugated monoclonal antibodies
   6.2. Immune checkpoint inhibitors
   6.3. Cancer vaccines
   6.4. Non-specific immunotherapies
   6.5. Others
7. Cancer Immunotherapy Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America 
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Cancer Immunotherapy – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Bristol Mayer’s Squibb
      9.1.1.  Introduction
      9.1.2. Financials
      9.1.3. Key Insights
      9.1.4. Key Strategy
      9.1.5. Product Portfolio
      9.1.6. SWOT Analysis
   9.2. F. Hoffmann-La Roche
      9.2.1. Introduction
      9.2.2. Financials
      9.2.3. Key Insights
      9.2.4. Key Strategy
      9.2.5. Product Portfolio
      9.2.6. SWOT Analysis
   9.3. Boehringer-Ingelheim      
      9.3.1.  Introduction
      9.3.2. Financials
      9.3.3. Key Insights
      9.3.4. Key Strategy
      9.3.5. Product Portfolio
      9.3.6. SWOT Analysis
   9.4. Pfizer Inc     
      9.4.1. Introduction
      9.4.2. Financials
      9.4.3. Key Insights
      9.4.4. Key Strategy
      9.4.5. Product Portfolio
      9.4.6. SWOT Analysis
   9.5. Sanofi   
      9.5.1. Introduction
      9.5.2. Financials
      9.5.3. Key Insights
      9.5.4. Key Strategy
      9.5.5. Product Portfolio
      9.5.6. SWOT Analysis
   9.6. Eli Lilly and Company     
      9.6.1. Introduction
      9.6.2. Financials
      9.6.3. Key Insights
      9.6.4. Key Strategy
      9.6.5. Product Portfolio
      9.6.6. SWOT Analysis
   9.7. Seattle Genetics  
      9.7.1. Introduction
      9.7.2. Financials
      9.7.3. Key Insights
      9.7.4. Key Strategy
      9.7.5. Product Portfolio
      9.7.6. SWOT Analysis
   9.8. Bayer Healthcare      
      9.8.1. Introduction
      9.8.2. Financials
      9.8.3. Key Insights
      9.8.4. Key Strategy
      9.8.5. Product Portfolio
      9.8.6. SWOT Analysis
   9.9. Intas Pharmaceuticals 
      9.9.1. Introduction
      9.9.2. Financials
      9.9.3. Key Insights
      9.9.4. Key Strategy
      9.9.5. Product Portfolio
      9.9.6. SWOT Analysis
   9.10. Novartis International AG      
      9.10.1. Introduction
      9.10.2. Financials
      9.10.3. Key Insights
      9.10.4. Key Strategy
      9.10.5. Product Portfolio
      9.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Immunotherapy is also known as biologic therapy for cancer treatment. Immunotherapy is treatment which is carried out using certain parts of a person’s immune system to fight diseases such as cancer. Immunotherapy is can be done in two ways which includes either stimulating person’s own immune system to work harder or smarter to attack cancer cells or injecting immune system components, such as man-made immune system proteins to fight against cancer cells. Globally increasing instances of deaths due to cancer and growing population with cancer coupled with increasing awareness about cancer and various available treatments to cure cancer are major driving factors for the growth of cancer immunotherapy market.

This report identifies the cancer immunotherapy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to cancer immunotherapy market.
Cancer Immunotherapy Market

Globally North America dominated the market for cancer immunotherapy in 2015 with accounting for nearly half of the global market due to high awareness and reported instances of cancer in the region. North America is expected to continue its domination during the period of study and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. However Asia-Pacific is expected to be the fastest growing market due to technological advancement in the field of medical science, increasing medical tourism, increased healthcare expenditure by many developing economies coupled with increasing awareness about cancer in the region.

This report on cancer immunotherapy also covers different type of various cancer treated and market size in various geographical regions.

  • On the basis of cancer treated with cancer immunotherapy this report covers all the major cancer treated using cancer immunotherapy: Cancer monoclonal antibodies (Naked monoclonal antibodies and Conjugated monoclonal antibodies), Immune checkpoint inhibitors, Cancer vaccines, Non-specific immunotherapies and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cancer immunotherapy in each of the region.

Sample Companies Profiled in this Report are: 
  • Bristol Mayer’s Squibb
  • F. Hoffmann-La Roche
  • Boehringer-Ingelheim      
  • Pfizer Inc     
  • Sanofi   
  • Eli Lilly and Company
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports